New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For OPXA;MKGAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 29, 2015
10:00 EDTMKGAYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:33 EDTMKGAYMerck KGaA initiated with a Neutral at Exane BNP Paribas
Subscribe for More Information
April 20, 2015
08:10 EDTOPXAOpexa Therapeutics to present biomarker data from NMO patients at AAN meeting
Opexa Therapeutics announced that it has been invited to present data on the immune profile of patients with NMO at the 67th American Academy of Neurology Annual Meeting in Washington D.C. Opexa will present the results of a study conducted to characterize the cellular immune profile of NMO patients prescribed B-cell depleting therapy in comparison to those of healthy donors. The results showed that despite administration of B-cell depleting therapy, inflammation continued to persist as did the presence of activated T-cells. Opexa has a preclinical development program in NMO and IND enabling activities are currently being conducted with its drug development candidate, OPX-212.
08:02 EDTMKGAYMerck KGaA, Pfizer initiate Phase III study with Avelumab
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use